KUALA LUMPUR: Duopharma Biotech Bhd
aims to deliver a satisfactory performance in 2024, underpinned by the positive advancements and anticipated growth in the economy and industry.
In a filing with Bursa Malaysia, the pharmaceutical company noted that it had encountered a myriad of challenges in 2023 which exerted pressure on its manufacturing margins, thus influencing the group’s overall profitability in 2023.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
